Sarepta Therapeutics

Sarepta Therapeutics shares made a handy gain to start the week after it announced a licensing agreement with Roche for its investigational gene therapy for Duchenne muscular dystrophy.
Sarepta shares jumped on Friday after the firm announced that the FDA has approved Vyondys 53 (golodirsen) for the treatment of Duchenne muscular dystrophy (DMD) in certain patients.
The top analyst upgrades, downgrades and initiations for Friday included Adobe, Biogen, Bristol-Myers, Broadcom, Charles Schwab, Ciena, Etsy, Gilead, Oracle, Sarepta, Snap and Wayfair.
Friday's top analyst upgrades, downgrades and initiations included Arista Networks, Booking, Dunkin' Brands, DuPont, GameStop, Generac, PBF Energy, Pinterest, Square and YETI.
Sarepta shares jumped on Friday after the firm announced an update from its Duchenne muscular dystrophy trial.
One sector that has avoided much of the current trade and recession fear turmoil is health care, and especially the biotech companies. The four top stocks have gigantic implied upside.
Tuesday was a breakout day for a few biotech companies that saw either huge gains or massive losses. 24/7 Wall St. has picked a few of those standouts to highlight.
The included AbbVie, Beyond Meat, Bio-Rad Laboratories, Dell Technologies, HP, Jumia Technologies, Nabriva Therapeutics, PG&E, and Sarepta Therapeutics.
With the market clearly close to, or at full value, it makes sense to look to areas where alpha can be generated for the rest of 2019. These five top stocks are the best picks from the Merrill team...
With the three major stock indexes trading at or near all-time highs, many investors are scratching their heads about where to look for new investment ideas at a time when interest rates have become...
Pfizer released initial clinical data from its Phase 1b gene therapy study for Duchenne muscular dystrophy. While these results did not necessarily live up to expectations, there is a winner in this.
These are the top analyst upgrades and downgrades for Friday, June 21, 2019. There are many stocks to Buy, including NLY, FISV, KEY, PSX and others.
Spark Therapeutics shares more than doubled in Tuesday’s session as the result of its pending acquisition. However, the root of the buyout was its gene therapy, which could drive more acquisitions...
Many Wall Street firms are issuing their top picks and listing their favorite sectors and trends to consider for the year ahead. Credit Suisse is one of those firms.
  After a big stock market sell-off and a subsequent snap-back rally, it’s always interesting to see how corporate directors are acting toward their own shares. It’s no secret that...